Valuation: Simcere Pharmaceutical Group Limited

Market Cap 3.97B 31.18B 3.43B 3.22B 2.93B 5.51B 380B 5.6B 37.78B 14.77B 190B 14.92B 14.59B 632B P/E 2026 *
15.7x
P/E 2027 * 13.6x
Enterprise Value 3.79B 29.71B 3.27B 3.07B 2.79B 5.25B 362B 5.34B 36.01B 14.08B 181B 14.22B 13.91B 602B EV / Sales 2026 *
2.53x
EV / Sales 2027 * 2.28x
Free-Float
32.48%
Yield 2026 *
3.39%
Yield 2027 * 3.91%
07-30 Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2026 CI
07-09 Simcere Pharma's Acute Ischemic Stroke Included in National Essential Medicines List MT
06-14 Simcere Pharma Gets China Nod for Tumor Drug Trial MT
06-12 Simcere Pharmaceutical Group Limited Receives Clinical Trial Approval for Sim0689 Pd-1/Vegf Bispecific Antibody CI
06-12 Simcere Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2025, Payable on or Before July 13, 2026 CI
06-12 Simcere Pharmaceutical Group Limited Enters into A Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis CI
06-01 Simcere Pharma Wins Promotion Rights for PrimeGenX's Atopic Dermatitis Drug MT
06-01 Simcere Pharmaceutical Group Limited Enters into Exclusive Promotion Service Agreement with PrimeGenX Therapeutics Co., Ltd CI
05-21 Simcere Pharmaceutical Group Limited Proposes to Declare A Final Dividend for the Year Ended December 31, 2025 CI
05-06 Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0613 LRRC15 Antibody Drug Conjugate CI
05-05 Simcere pharmaceutical receives NMPA China clinical trial approval for SIM0613 RE
05-05 Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug MT
05-03 Wuxi Biocity Biopharmaceutics Co., Ltd. announced that it has received funding from Simcere Pharmaceutical Group Limited, First Light Capital CI
1 day-0.25%
1 week-2.49%
Current month-1.70%
1 month-3.19%
3 months+4.57%
6 months-5.82%
Current year+1.42%
1 week 12.02
Extreme 12.02
12.8
1 month 11.63
Extreme 11.63
13.52
Current year 9.07
Extreme 9.07
14.28
1 year 9.07
Extreme 9.07
15.08
3 years 4.94
Extreme 4.94
15.08
5 years 4.94
Extreme 4.94
15.08
10 years 4.94
Extreme 4.94
15.08
Manager TitleAgeSince
Chief Executive Officer 54 2026-03-24
Director of Finance/CFO 55 2019-11-18
Chief Tech/Sci/R&D Officer 51 2023-11-30
Director TitleAgeSince
Chairman 63 2012-10-07
Director/Board Member 55 2019-11-18
Director/Board Member 46 2019-10-31
Date Insider Type Main position Quantity % Market Cap.
7/13/26 Other

Founder

-47,000 0.0018%
7/13/26 Other

Director

-47,000 0.0018%
7/10/26 Other

Founder

-53,000 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%-2.49%-2.96%+89.39% 3.97B
-0.10%-0.77%+17.58%+70.16% 48.43B
-3.26%-5.31%+53.19%+117.23% 39.72B
-0.60%-0.94%-7.29%+17.35% 12.25B
-2.75%+1.88%+14.81%+76.92% 11.84B
-0.19%-0.38%+30.40%+135.91% 9.06B
+1.56%+5.52%+23.46%+39.78% 7.57B
+0.52%+2.08%+40.75%-12.45% 7.18B
-0.07%+1.72%+13.39%+190.65% 6.84B
-2.51%-3.14%-27.46%+24.20% 5.77B
Average -0.77%+1.28%+15.59%+74.91% 15.26B
Weighted average by Cap. -1.16%+0.98%+24.35%+81.37%

Financials

2026 *2027 *
Net sales 1.49B 11.73B 1.29B 1.21B 1.1B 2.07B 143B 2.11B 14.21B 5.56B 71.57B 5.61B 5.49B 238B 1.69B 13.25B 1.46B 1.37B 1.25B 2.34B 161B 2.38B 16.06B 6.28B 80.84B 6.34B 6.2B 269B
Net income 246M 1.93B 213M 200M 182M 341M 23.53B 347M 2.34B 915M 11.78B 924M 904M 39.16B 292M 2.29B 253M 237M 216M 406M 27.96B 412M 2.78B 1.09B 14B 1.1B 1.07B 46.53B
Net Debt -187M -1.47B -161M -152M -138M -259M -17.87B -264M -1.78B -695M -8.95B -702M -686M -29.74B -123M -962M -106M -99.48M -90.48M -170M -11.72B -173M -1.17B -456M -5.87B -460M -450M -19.51B
Logo Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces various drugs, including Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
7,038
Date Price Change Volume
26-08-14 HK$12.14 -0.25% 4,102,000
26-08-13 HK$12.17 -0.41% 5,498,406
26-08-12 HK$12.22 -1.05% 4,068,040
26-08-11 HK$12.35 0.00% 7,020,200
26-08-10 HK$12.35 -0.80% 5,447,000
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.43CNY
Average target price
15.33CNY
Spread / Average Target
+46.91%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2096 Stock